Biotechnology

Achieve Life Sciences

Achieve Life Sciences released FY2026 Q1 earnings on May 12 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1904 (forecast USD -0.2985)

Achieve Life Sciences to Release FY2026 Q1 Earnings on May 12, Pre-Market EST, Forecast EPS USD -0.2985

Achieve Life Sciences Introduces Nicotine Dependence Treatment Drug Cytisinicline

Achieve Life Sciences released FY2025 Q4 earnings on March 24 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2752 (forecast USD -0.2737)

Achieve Life Sciences released FY2025 earnings on March 24 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2535 (forecast USD -1.2612)

Achieve Life Sciences to release FY2025 Q4 earnings report on March 24 Pre-Market EST, forecast EPS USD -0.2737

Lake Street analyst reiterates buy rating on Achieve Life Sciences

JonesTrading Analyst Reiterates Buy Rating on ACHV Stock

Achieve Life Sciences released FY2025 Q3 earnings on November 6 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.283 (forecast USD -0.2571)

Achieve Life Sciences released FY2025 9 Months earnings on November 6 Pre-Market (EST), actual revenue USD 0, actual EPS USD -1.0195

Achieve Life Sciences Outlines Strategy for Nicotine Dependence Treatment Drug

Achieve Life Sciences FY2025 Q3 Earnings Release on November 6, 2025 Pre-Market EST, Forecast EPS -0.2571 USD

H.C. Wainwright Reiterates Buy Rating on Achieve Life Sciences

Achieve Life Sciences released FY2025 Q2 earnings on August 7 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.37 (forecast USD -0.355)

Achieve Life Sciences released FY2025 Semi-Annual earnings on August 7 Pre-Market EST, actual revenue USD 0, actual EPS USD -0.7364

Achieve Life Sciences to Release FY2025 Q2 Earnings on August 7, Pre-Market EST, Forecast EPS -0.355 USD

Achieve Life Sciences Outlines Nicotine Addiction Treatment Strategy

Rogue Funds Analyzes Achieve Life Sciences Stock Performance

Achieve Life Sciences Submits NDA for Smoking Cessation Product

Achieve Life Sciences Price IPO at $3 Per Share and Raise $45 Million

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ACHV

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment | ACHV Stock News

StockTitan

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment | ACHV Stock News

Maxim Group analyst Jason McCarthy reaffirmed a Buy rating on Achieve Life Sciences with a $10 price target, citing the company's strengthened financial position and promising clinical data for cytisinicline. The recent $354M financing extends the company's runway for U.S. approval and a new Phase 3 trial. The leadership refresh and positive Phase 3 data support confidence in the drug's commercialization. Lake Street also maintained a Buy rating with an $11 price target.

Tip Ranks

Moleculin Biotech

Medicus Pharma

Plus Therapeutics

MEDICUS PHARMA LTD C/WTS 15/11/2029(TO PUR COM)

Achieve Life Sciences Reaffirmed at Buy as Financing, Leadership Refresh, and Strong Cytisinicline Data Support Unchanged $10 Price Target

Lake Street analyst Mark Smith has reaffirmed a Buy rating for Achieve Life Sciences (ACHV) with a price target of $11.00. Smith, a 4-star analyst with a 44.29% success rate, indicates a Strong Buy consensus for ACHV, which has an average price target of $13.20 according to analysts. He also covers other stocks in the Consumer Cyclical sector.

Clarus

Lakeland Industries

Red Robin Gourmet

Lake Street Sticks to Its Buy Rating for Achieve Life Sciences (ACHV)

H.C. Wainwright analyst Brandon Folkes has reiterated a Buy rating on Achieve Life Sciences (ACHV) with a price target of $12.00. Folkes, a 3-star analyst, has an average return of 2.0% and a 42.07% success rate. The overall analyst consensus for Achieve Life Sciences is a Strong Buy, with an average price target of $13.20.

Heron Therap

Collegium Pharma

Achieve Life Sciences (ACHV) Gets a Buy from H.C. Wainwright

Achieve Life Sciences (NASDAQ:ACHV) reported its Q1 2026 results, highlighting a $180 million capital raise and potential additional funding of $174 million. The company is focused on developing cytosinicline for smoking and vaping cessation, with an NDA resubmission planned for Q4 2026 and a commercial launch expected in H1 2027. Operational advancements include a partnership with Adair Pharma Solutions for U.S. manufacturing and new leadership appointments to enhance market readiness. The scientific data supports cytosinicline's efficacy in addressing unmet needs in smoking cessation.

benzinga_article

Tarsus Pharmaceuticals

Achieve Life Sciences Reports Q1 2026 Results: Full Earnings Call Transcript

Achieve Life Sciences has appointed Christopher Martin to its board as part of ongoing transitions, with a $40,000 retainer and stock options. Long-time chairman Thomas King will resign on June 8, with Lucian Iancovici, MD, taking over. Chief Commercial Officer Jaime Xinos will leave on May 31, as the company reorganizes ahead of the cytisinicline launch. Analysts rate ACHV stock as a Buy with a $13.00 target, though Spark's AI Analyst gives it a Neutral score due to weak financials and cash burn, despite regulatory progress and financing improvements.

Achieve Life Sciences Adds Director Amid Board Transitions

Earnings Watch

Achieve Life Sciences | 10-Q: FY2026 Q1 Revenue: USD 0

Achieve Life Sciences(ACHV.US)

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment | ACHV Stock News

Achieve Life Sciences Reaffirmed at Buy as Financing, Leadership Refresh, and Strong Cytisinicline Data Support Unchanged $10 Price Target

Lake Street Sticks to Its Buy Rating for Achieve Life Sciences (ACHV)

Achieve Life Sciences (ACHV) Gets a Buy from H.C. Wainwright

Achieve Life Sciences Reports Q1 2026 Results: Full Earnings Call Transcript

Achieve Life Sciences Adds Director Amid Board Transitions

Achieve Life Sciences | 10-Q: FY2026 Q1 Revenue: USD 0